Pathway-Based Multi-Omics Data Integration for Breast Cancer Diagnosis and Prognosis.

Ph.D. Thesis. University of Hawaiʻi at Mānoa 2017

Unveiling Novel Glioma Biomarkers through Multi-omics Integration and Classification

Glioma is currently one of the most prevalent types of primary brain cancer. Given its high level of heterogeneity along with the complex biological molecular markers, many efforts have been made to accurately classify the type of glioma in each patient, which, in turn, is critical to improve early diagnosis and increase survival. Nonetheless, as a result of the fast- growing technological advances in high throughput sequencing and evolving molecular understanding of glioma biology, its classification has been recently subject to significant alterations. In this study, multiple glioma omics modalities (including mRNA, DNA methylation, and miRNA) from The Cancer Genome Atlas (TCGA) are integrated, while using the revised glioma reclassified labels, with a supervised method based on sparse canonical correlation analysis (DIABLO) to discriminate between glioma types. It was possible to find a set of highly correlated features distinguishing glioblastoma from low- grade gliomas (LGG) that were mainly associated with the disruption of receptor tyrosine kinases signaling pathways and extracellular matrix organization and remodeling. On the other hand, the discrimination of the LGG types was characterized primarily by features involved in ubiquitination and DNA transcription processes. Furthermore, several novel glioma biomarkers likely helpful in both diagnosis and prognosis of the patients were identified, including the genes PPP1R8, GPBP1L1, KIAA1614, C14orf23, CCDC77, BVES, EXD3, CD300A and HEPN1. Overall, this classification method allowed to discriminate the different TCGA glioma patients with very high performance, while seeking for common information across multiple data types, ultimately enabling the understanding of essential mechanisms driving glioma heterogeneity and unveiling potential therapeutic targets.O glioma é atualmente um dos tipos mais prevalentes de cancro cerebral primário. Dado o seu elevado nível de heterogeneidade e dada a complexidade dos seus marcadores moleculares biológicos, muitos esforços têm sido realizados para classificar com precisão o tipo de glioma em cada paciente, o que, por sua vez, é fundamental para melhorar o diagnóstico precoce e aumentar a sobrevivência. No entanto, como resultado dos avanços tecnológicos em rápido crescimento na sequenciação de dados e na evolução da com- preensão molecular da biologia do glioma, a sua classificação foi recentemente sujeita a alterações significativas. Neste estudo, múltiplas modalidades ómicas de glioma (in- cluindo mRNA, metilação de DNA e miRNA) provenientes do The Cancer Genome Atlas (TCGA) são integradas, juntamente com a utilização das classes revistas e reclassificadas de glioma, com um método supervisionado baseado em análise de correlação canónica esparsa (DIABLO) para discriminar entre os tipos de glioma. Foi possível encontrar um conjunto de características altamente correlacionadas que distinguem o glioblastoma dos gliomas de baixo grau (LGG) que estavam principalmente associadas à ruptura das vias de sinalização dos receptores de tirosina quinases e à organização e remodelação da matriz extracelular. Por outro lado, a discriminação dos tipos LGG foi caracterizada principalmente por variáveis envolvidas nos processos de ubiquitinação e transcrição de DNA. Além disso, foram identificados vários novos biomarcadores de glioma potencial- mente úteis tanto no diagnóstico quanto no prognóstico dos pacientes, incluindo os genes PPP1R8, GPBP1L1, KIAA1614, C14orf23, CCDC77, BVES, EXD3, CD300A e HEPN1. No geral, este método de classificação permitiu discriminar com desempenho muito elevado os diferentes pacientes com glioma, simultaneamente procurando informações comuns entre os vários tipos de dados, permitindo, em última análise, a compreensão de mecanis- mos essenciais que impulsionam a heterogeneidade em glioma e revelam potenciais alvos terapêuticos

A Machine Learning Framework for Identifying Molecular Biomarkers from Transcriptomic Cancer Data

Cancer is a complex molecular process due to abnormal changes in the genome, such as mutation and copy number variation, and epigenetic aberrations such as dysregulations of long non-coding RNA (lncRNA). These abnormal changes are reflected in transcriptome by turning oncogenes on and tumor suppressor genes off, which are considered cancer biomarkers. However, transcriptomic data is high dimensional, and finding the best subset of genes (features) related to causing cancer is computationally challenging and expensive. Thus, developing a feature selection framework to discover molecular biomarkers for cancer is critical. Traditional approaches for biomarker discovery calculate the fold change for each gene, comparing expression profiles between tumor and healthy samples, thus failing to capture the combined effect of the whole gene set. Also, these approaches do not always investigate cancer-type prediction capabilities using discovered biomarkers. In this work, we proposed a machine learning-based framework to address all of the above challenges in discovering lncRNA biomarkers. First, we developed a machine learning pipeline that takes lncRNA expression profiles of cancer samples as input and outputs a small set of key lncRNAs that can accurately predict multiple cancer types. A significant innovation of our work is its ability to identify biomarkers without using healthy samples. However, this initial framework cannot identify cancer-specific lncRNAs. Second, we extended our framework to identify cancer type and subtype-specific lncRNAs. Third, we proposed to use a state-of-the-art deep learning algorithm concrete autoencoder (CAE) in an unsupervised setting, which efficiently identifies a subset of the most informative features. However, CAE does not identify reproducible features in different runs due to its stochastic nature. Thus, we proposed a multi-run CAE (mrCAE) to identify a stable set of features to address this issue. Our deep learning-based pipeline significantly extended the previous state-of-the-art feature selection techniques. Finally, we showed that discovered biomarkers are biologically relevant using literature review and prognostically significant using survival analyses. The discovered novel biomarkers could be used as a screening tool for different cancer diagnoses and as therapeutic targets

Systems Analytics and Integration of Big Omics Data

A “genotype"" is essentially an organism's full hereditary information which is obtained from its parents. A ""phenotype"" is an organism's actual observed physical and behavioral properties. These may include traits such as morphology, size, height, eye color, metabolism, etc. One of the pressing challenges in computational and systems biology is genotype-to-phenotype prediction. This is challenging given the amount of data generated by modern Omics technologies. This “Big Data” is so large and complex that traditional data processing applications are not up to the task. Challenges arise in collection, analysis, mining, sharing, transfer, visualization, archiving, and integration of these data. In this Special Issue, there is a focus on the systems-level analysis of Omics data, recent developments in gene ontology annotation, and advances in biological pathways and network biology. The integration of Omics data with clinical and biomedical data using machine learning is explored. This Special Issue covers new methodologies in the context of gene–environment interactions, tissue-specific gene expression, and how external factors or host genetics impact the microbiome

Large-Scale and Pan-Cancer Multi-omic Analyses with Machine Learning

Multi-omic data analysis has been foundational in many fields of molecular biology, including cancer research. Investigation of the relationship between different omic data types reveals patterns that cannot otherwise be found in a single data type alone. With recent technological advancements in mass spectrometry (MS), MS-based proteomics has enabled the quantification of thousands of proteins in hundreds of cell lines and human tissue samples. This thesis presents several machine learning-based methods that facilitate the integrative analysis of multi-omic data. First, we reviewed five existing multi-omic data integration methods and performed a benchmarking analysis, using a large-scale multi-omic cancer cell line dataset. We evaluated the performance of these machine learning methods for drug response prediction and cancer type classification. Our result provides recommendations to researchers regarding optimal machine learning method selection for their applications. Second, we generated a pan-cancer proteomic map of 949 cancer cell lines across 40 cancer types and developed a machine learning method DeeProM to analyse the multi-omic information of these lines. This pan-cancer proteomic map (ProCan-DepMapSanger) is now publicly available and represents a major resource for the scientific community, for biomarker discovery and for the study of fundamental aspects of protein regulation. Third, we focused on publicly available multi-omic datasets of both cancer cell lines and human tissue samples and developed a Transformer-based deep learning method, DeePathNet, which integrates human knowledge with machine intelligence. We applied DeePathNet on three evaluation tasks, namely drug response prediction, cancer type classification and breast cancer subtype classification. Taken together, our analyses and methods allowed more accurate cancer diagnosis and prognosis

The HBP1 tumor suppressor is a negative epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

C

Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies

Cutaneous melanoma is an aggressive tumor responsible for 90% of mortality related to skin cancer. In the recent years, the discovery of driving mutations in melanoma has led to better treatment approaches. The last decade has seen a genomic revolution in the field of cancer. Such genomic revolution has led to the production of an unprecedented mole of data. High-throughput genomic technologies have facilitated the genomic, transcriptomic and epigenomic profiling of several cancers, including melanoma. Nevertheless, there are a number of newer genomic technologies that have not yet been employed in large studies. In this article we describe the current classification of cutaneous melanoma, we review the current knowledge of the main genetic alterations of cutaneous melanoma and their related impact on targeted therapies, and we describe the most recent highthroughput genomic technologies, highlighting their advantages and disadvantages. We hope that the current review will also help scientists to identify the most suitable technology to address melanoma-related relevant questions. The translation of this knowledge and all actual advancements into the clinical practice will be helpful in better defining the different molecular subsets of melanoma patients and provide new tools to address relevant questions on disease management. Genomic technologies might indeed allow to better predict the biological - and, subsequently, clinical - behavior for each subset of melanoma patients as well as to even identify all molecular changes in tumor cell populations during disease evolution toward a real achievement of a personalized medicine

Smoking and Second Hand Smoking in Adolescents with Chronic Kidney Disease: A Report from the Chronic Kidney Disease in Children (CKiD) Cohort Study

The goal of this study was to determine the prevalence of smoking and second hand smoking [SHS] in adolescents with CKD and their relationship to baseline parameters at enrollment in the CKiD, observational cohort study of 600 children (aged 1-16 yrs) with Schwartz estimated GFR of 30-90 ml/min/1.73m2. 239 adolescents had self-report survey data on smoking and SHS exposure: 21 [9%] subjects had “ever” smoked a cigarette. Among them, 4 were current and 17 were former smokers. Hypertension was more prevalent in those that had “ever” smoked a cigarette (42%) compared to non-smokers (9%), p\u3c0.01. Among 218 non-smokers, 130 (59%) were male, 142 (65%) were Caucasian; 60 (28%) reported SHS exposure compared to 158 (72%) with no exposure. Non-smoker adolescents with SHS exposure were compared to those without SHS exposure. There was no racial, age, or gender differences between both groups. Baseline creatinine, diastolic hypertension, C reactive protein, lipid profile, GFR and hemoglobin were not statistically different. Significantly higher protein to creatinine ratio (0.90 vs. 0.53, p\u3c0.01) was observed in those exposed to SHS compared to those not exposed. Exposed adolescents were heavier than non-exposed adolescents (85th percentile vs. 55th percentile for BMI, p\u3c 0.01). Uncontrolled casual systolic hypertension was twice as prevalent among those exposed to SHS (16%) compared to those not exposed to SHS (7%), though the difference was not statistically significant (p= 0.07). Adjusted multivariate regression analysis [OR (95% CI)] showed that increased protein to creatinine ratio [1.34 (1.03, 1.75)] and higher BMI [1.14 (1.02, 1.29)] were independently associated with exposure to SHS among non-smoker adolescents. These results reveal that among adolescents with CKD, cigarette use is low and SHS is highly prevalent. The association of smoking with hypertension and SHS with increased proteinuria suggests a possible role of these factors in CKD progression and cardiovascular outcomes